IMAGE: Before and after images of a single patient with end-stage metastatic prostate cancer treated with Actinium-225. The first image was taken before treatment, the second after three doses of Actinium-225,… view more
Credit: Clemens Kratochwil et al. J Nucl Med 2016;57:1941-1944
Vancouver, BC and Chalk River, ON – September 27, 2018 – TRIUMF, Canada’s particle accelerator centre, and Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.
An alpha-emitting isotope with a short half-life, Actinium-225 can be combined with a protein or antibody that specifically targets cancer cells, creating a revolutionary treatment that is extremely effective at killing cancer cells without doing damage to surrounding, healthy cells.
Currently, the annual supply of Actinium-225 from global sources enables an extremely limited number of patient treatments, which is why the isotope is nicknamed “the rarest drug on Earth.” Under terms of the partnership, TRIUMF’s high energy proton beam will be used to manufacture the isotope, while CNL’s nuclear-licensed handling and production facilities will be used to
Article originally posted at